All In Biotech

Drug Trial Radar · NCT04333914

Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection

A Prospective, Controlled, Randomized, Multicenter Study of the Efficacy of an Autophagy Inhibitor (GNS561), an Anti-NKG2A (Monalizumab) and an Anti-C5aR (Avdoralimab) Compared to the Standard of Care in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 (COVID-19) Infection.

Last checked: Nov 19, 2026Latest source record: Sep 30, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

19

Actual

Start

Apr 15, 2020

Primary completion

Jul 6, 2021

Study completion Dec 31, 2021

Sponsor

Lead sponsor
Centre Leon BerardAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 3, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A prospective, controlled, randomized, multicenter study whose goal is to compare the efficacy of an autophagy inhibitor (GNS561), an anti-NKG2A (monalizumab) and an anti-C5aR (avdoralimab) versus standard of care in patients with advanced or metastatic cancer who have Sars-CoV-2 infection not eligible to a resuscitation unit. According to their severity level at the time of enrolment, eligible patients will be randomized into 2 different cohorts: * COHORT 1 (mild symptoms or asymptomatic): GNS561 vs anti-NKG2A vs standard of care (randomization ratio 1:1:1). * COHORT 2 (moderate/severe symptoms): anti-C5aR vs standard of care (randomization ratio 1:1).

Conditions

  • SARS-CoV-2 (COVID-19) Infection
  • Advanced or Metastatic Hematological or Solid Tumor

Interventions

  • Autophagy inhibitor (GNS651)Drug

    Cohort 1 (arm B): 200mg q.d. orally for 10 consecutive days. If for any reason a treatment is not given within the allowed treatment window (± 12h) it will be cancelled (i.e., missed for that time point), and treatment will be resumed at the next dosing day.

  • Standard of careOther

    In cohorts 1 and 2, patients allocated in the standard of care arms should receive best supportive care, as per the investigator's discretion and the local routine practices. With regards to the respiratory symptoms and medical resoures at investigational site, the following should be given according to the patient's condition: oxygen supplementation, non-invasive ventilation, invasive ventilation, antibiotherapy, vasopressor support, renal replacement therapy, or extracorporeal membrane oxygenation. Additional care and medications should be administered in the patient's best interest.

  • AvdoralimabDrug

    Cohorte 2 (arm H): 500mg, intravenously, at Day 1 then 200mg once daily every 2 days during 14 Days

  • MonalizumabDrug

    Cohorte 2 (arm G) : 50mg (flat dose),intravenously, single infusion at Day 1.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 28-day survival rateTime frame: 28 days from randomization

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Centre Jean Perrin

    Clermont-Ferrand, France

  • CHU Clermont Ferrand

    Clermont-Ferrand, France

  • Centre Oscar Lambret

    Lille, France

  • AP-HP Hôpital Saint Antoine

    Paris, France

  • AP-HP La Pitié Salpétrière

    Paris, France

  • Hôpital Saint-Joseph

    Paris, France

  • AP-HP Tenon

    Paris, France

  • AP-HP Hôpital Bichat Claude Bernard

    Paris, France

  • GH Diaconesses Croix Saint Simon

    Paris, France

  • Institut de cancérologie Strasbourg Europe (ICANS)

    Strasbourg, France

  • Institut Gustave Roussy

    Villejuif, France

  • Centre Léon Bérard

    Lyon, Rhône, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.